Japan society of clinical oncology clinical practice guidelines 2024 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2
In brief
Japan's updated cancer fertility guidelines call for individualized, team-based decisions
Updated guidance covers fertility preservation and reproductive support across five cancer areas in children, adolescents, and young adults. Because evidence is limited for several questions, choices should reflect age, disease, treatment plans and urgency, and the patient's reproductive wishes. The guidelines put cancer treatment first and stress timely counseling and collaboration across specialties.
- Journal
- International journal of clinical oncology (Q1)
- Published
- 18 November 2026
- Study design
- Practice guideline / consensus
- Evidence level
- Level 1, High (CEBM 1c)
- Authors
- Nozomi Takahashi, Miyuki Harada, Satoshi Tamauchi, Ryoko Ichikawa, Arisa Ueki, Taisuke Mori, et al.
- PMID
- 43050070
- DOI
- 10.1007/s10147-026-03235-4
Why clinicians should know about it
- Picked for Hematology (top studies of the week, 22 November 2026): Fertility preservation guidance includes hematologic malignancies
Abstract
BACKGROUND: The Japan Society of Clinical Oncology (JSCO) Clinical Practice Guidelines 2024 for Fertility Preservation in Childhood, Adolescent, and Young Adult (CAYA) Cancer Patients and Related Diseases provide updated guidance for oncofertility care in Japan. This article, Part 2 of the guideline series, addresses gynecologic, breast, and urologic cancers; childhood cancer and related diseases; and hematologic malignancies. METHODS: Background Questions (BQs), Clinical Questions (CQs), and Future Questions (FQs) were developed for each disease area. CQs were addressed through systematic reviews and resulted in evidence-based recommendations, whereas BQs summarized established clinical knowledge and FQs addressed important issues for which evidence-based recommendations could not be formulated. Recommendations were developed through systematic review and consensus processes using the Evidence-to-Decision framework, with consideration of the certainty of evidence, benefits and harms, patient values, acceptability, and feasibility. RESULTS: Disease-specific recommendations, statements, and explanatory texts are presented for fertility preservation and reproductive support in the five clinical areas. Because evidence remains limited for several clinical issues, decisions should be individualized according to the patient's age, disease status, planned treatment, urgency of treatment initiation, and reproductive wishes. CONCLUSIONS: These guidelines emphasize prioritization of cancer treatment, timely individualized counseling, and multidisciplinary collaboration among oncologists, reproductive medicine specialists, pediatricians, nurses, and other healthcare professionals. Such collaboration is essential to support informed decision-making and optimize oncofertility care for CAYA patients.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.